Clinical Trials
17 trialsNCT03219333 2024-08-27
EV-201
Astellas Pharma Inc
Phase 2 Completed
NCT03513952 2024-07-26
Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT03617913 2023-01-06
Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer
Mayo Clinic
Phase 2 Completed
NCT03520231 2021-11-23
Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases
University Health Network, Toronto
Phase 2 Completed
NCT00749892 2020-09-10
Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02178241 2019-12-16
Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT02665039 2019-10-08
VINGEM
Karolinska University Hospital
Phase 2 Completed
NCT01282463 2019-09-09
Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
Eli Lilly and Company
Phase 2 Completed
NCT01191892 2019-05-16
Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer
Cardiff University
Phase 2 Completed
NCT02438865 2018-09-13
Prophylactic Intravesical Chemotherapy After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: a Randomized Controlled Trial Between Single Postoperative Dose Versus Maintenance Therapy.
Mansoura University
Phase 2 Completed
NCT01328574 2017-01-13
TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00072150 2013-06-05
Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00009867 2013-06-04
Arsenic Trioxide in Treating Patients With Urothelial Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01426126 2011-12-07
Study of Genexol-PM in Patients With Advanced Urothelial Cancer Previously Treated With Gemcitabine and Platinum
Asan Medical Center
Phase 2 Completed
NCT00661609 2011-01-12
A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer
AstraZeneca
Phase 2 Completed
NCT00101608 2010-03-02
Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium
Bristol-Myers Squibb
Phase 2 Completed
NCT00077688 2009-06-04
TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium
Achieve Life Sciences
Phase 2 Completed